2021
Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia
Gorfinkel L, Demsky C, Pashankar F, Kupfer G, Shah NC. Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia. Pediatric Transplantation 2021, 25: e14009. PMID: 33755277, DOI: 10.1111/petr.14009.Peer-Reviewed Original ResearchConceptsUnrelated donor transplantsDonor transplantsBM graftsVivo T-cell depletionReduced intensity conditioning regimenStem cell transplant programInclusion of alemtuzumabNon-TBI conditioningPost-transplant complicationsSuccess of HSCTDevelopment of GVHDT-cell depletionIntensity conditioning regimenBone marrow transplantFull immune reconstitutionChronic GVHDCyclophosphamide conditioningGVHD prophylaxisMSD transplantsImmune reconstitutionConditioning regimenLate complicationsConditioning regimensSecondary neoplasmsSecondary malignancies
2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant
Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, Margossian SP, Mauguen A, Prockop S, Scaradavou A, Shah N, Spitzer B, Stieglitz E, Yeager N, O’Reilly R, Brentjens RJ, Jan Boelens J, Curran KJ. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation 2020, 55: 2160-2169. PMID: 32390002, PMCID: PMC7606268, DOI: 10.1038/s41409-020-0926-1.Peer-Reviewed Original ResearchConceptsCAR T cellsAllo-HSCTT cellsCumulative incidenceCell transplantAllogeneic hematopoietic stem cell transplantAllogeneic hematopoietic cell transplantHematopoietic stem cell transplantCAR T-cell therapyConsolidative allo-HSCTHematopoietic cell transplantYoung adult patientsFavorable overall survivalStem cell transplantT-cell therapyFavorable OSOverall survivalAdult patientsSevere toxicitySmall cohortDisease controlPatientsCD34IncidenceRelapse
2018
CAR‐T cell manufacture: snatching victory when defeat is looming
Gowda L, Shah NC. CAR‐T cell manufacture: snatching victory when defeat is looming. Transfusion 2018, 58: 1335-1337. PMID: 29949188, DOI: 10.1111/trf.14760.Peer-Reviewed Original Research